Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 2/20 | 0.70 |
| ▸ | MAOB | P27338 | 1/20 | 0.69 |
| ▸ | TTR | P02766 | 2/20 | 0.59 |
| ▸ | DPP4 | P27487 | 1/20 | 0.59 |
| ▸ | TUBB1 | Q9H4B7 | 6/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | ACHE | P22303 | 4/20 | 0.57 |
| ▸ | BCHE | P06276 | 3/20 | 0.57 |
| ▸ | CA12 | O43570 | 1/20 | 0.56 |
| ▸ | CA1 | P00915 | 1/20 | 0.56 |
| ▸ | CA2 | P00918 | 1/20 | 0.56 |
| ▸ | CA7 | P43166 | 1/20 | 0.56 |
| ▸ | CA9 | Q16790 | 1/20 | 0.56 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3678457 | 1.00 | FDPS (0.70) | FDPSMAOBTTRDPP4TUBB1 | |
| SCHEMBL30594189 | 1.00 | FDPS (0.70) | FDPSMAOBTTRDPP4TUBB1 | |
| SCHEMBL5366819 | 0.89 | MAOB (0.73) | FDPSMAOBTTRDPP4CYP3A4 | |
| SCHEMBL5353419 | 0.89 | MAOB (0.73) | FDPSMAOBTTRDPP4CYP3A4 | |
| SCHEMBL8046251 | 0.87 | FDPS (0.84) | FDPSMAOBTTRDPP4ACHE | |
| SCHEMBL31087309 | 0.87 | FDPS (0.84) | FDPSMAOBTTRDPP4ACHE | |
| SCHEMBL28859350 | 0.87 | FDPS (0.84) | FDPSMAOBTTRDPP4ACHE | |
| SCHEMBL8046247 | 0.87 | FDPS (0.84) | FDPSMAOBTTRDPP4ACHE | |
| SCHEMBL28859349 | 0.87 | FDPS (0.84) | FDPSMAOBTTRDPP4ACHE | |
| SCHEMBL6821280 | 0.85 | EPHX2 (0.66) | FDPSTTRTUBB1CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210137110-A1 | USE OF CINNAMATE COMPOUNDS IN THE CONTROL OF FUNGAL DISEASES OF CROPS | INSTITUTE OF PLANT PROTECTION, GANSU ACADEMY OF AGRICULTURAL SCIENCES (CN) | 2021-05-13 | — | — | US | claimed |
| CN-117062813-A | Polycyclic compound and application thereof | 四川汇宇制药股份有限公司 | 2023-11-14 | — | — | CN | disclosed |
| US-11533912-B2 | Use of cinnamate compounds in the control of fungal diseases of crops | INSTITUTE OF PLANT PROTECTION, GANSU ACADEMY OF AGRICULTURAL SCIENCES (CN) | 2022-12-27 | — | — | US | disclosed |
| US-20210137110-A1 | USE OF CINNAMATE COMPOUNDS IN THE CONTROL OF FUNGAL DISEASES OF CROPS | INSTITUTE OF PLANT PROTECTION, GANSU ACADEMY OF AGRICULTURAL SCIENCES (CN) | 2021-05-13 | — | — | US | disclosed |
| EP-2914580-B1 | THIOARYL DERIVATIVES AS GPR120 AGONISTS | LG CHEMICAL LTD (KR) | 2019-02-20 | — | — | EP | disclosed |
| US-9447044-B2 | Thioaryl derivatives as GPR120 agonists | LG LIFE SCIENCES LTD. (KR) | 2016-09-20 | — | — | US | disclosed |
| US-20150291527-A1 | THIOARYL DERIVATIVES AS GPR120 AGONISTS | LG LIFE SCIENCES LTD. (KR) | 2015-10-15 | — | — | US | disclosed |
| EP-2914580-A1 | THIOARYL DERIVATIVES AS GPR120 AGONISTS | LG Life Sciences Ltd. (KR) | 2015-09-09 | — | — | EP | disclosed |
| WO-2014069963-A1 | THIOARYL DERIVATIVES AS GPR120 AGONISTS | LG LIFE SCIENCES LTD. (KR) | 2014-05-08 | — | — | WO | disclosed |
| US-20100048893-A1 | Substituted arylalkanoic acid derivatives and use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2010-02-25 | — | — | US | disclosed |
| US-20090062530-A1 | Substituted arylalkanoic acid derivatives and use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2009-03-05 | — | — | US | disclosed |
| EP-1477472-B1 | SUBSTITUTED PHENYLALKANOIC ACID DERIVATIVE AND USE THEREOF | ASAHI KASEI PHARMA CORP (JP) | 2009-01-14 | — | — | EP | disclosed |
| US-7470807-B2 | Suppress production of both prostaglandins and leukotrienes and have reduced side effects; treatment of various inflammatory diseases, autoimmune diseases, allergic diseases, pain and fibrosis; for example, methyl 3-[3-acetylamino-4-cyclopentyloxy-5-(naphthalen-2-yl)phenyl]propionate | ASAHI KASEI PHARMA CORPORATION (JP) | 2008-12-30 | — | — | US | disclosed |
| US-20070213333-A1 | Substituted arylalkanoic acid derivatives and use thereof | ASAHI KASEI PHAMA CORPORATION (JP) | 2007-09-13 | — | — | US | disclosed |
| EP-1660427-A4 | SUBSTITUTED ARYLALKANOIC ACID DERIVATIVE AND USE THEREOF | ASAHI KASEI PHARMA CORP (JP) | 2006-12-20 | — | — | EP | disclosed |
| EP-1660427-A1 | SUBSTITUTED ARYLALKANOIC ACID DERIVATIVE AND USE THEREOF | Asahi Kasei Pharma Corporation (JP) | 2006-05-31 | — | — | EP | disclosed |
| US-6867320-B2 | Substituted phenylalkanoic acid derivatives and use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2005-03-15 | — | — | US | disclosed |
| WO-2005016862-A1 | SUBSTITUTED ARYLALKANOIC ACID DERIVATIVE AND USE THEREOF | ASAHI KASEI PHARMA CORPORATION (JP) | 2005-02-24 | — | — | WO | disclosed |
| EP-1477472-A1 | SUBSTITUTED PHENYLALKANOIC ACID DERIVATIVE AND USE THEREOF | Asahi Kasei Pharma Corporation (JP) | 2004-11-17 | — | — | EP | disclosed |
| US-20040044258-A1 | Substituted phenylalkanoic acid derivatives and use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2004-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150291527-A1 | THIOARYL DERIVATIVES AS GPR120 AGONISTS | GPR119, GLP1R, GCGR | FDPS 1883/4885MAOB 4387/4885TTR 2849/4885 |
| US-20210137110-A1 | USE OF CINNAMATE COMPOUNDS IN THE CONTROL OF FUNGAL DISEASES OF CROPS | CROCC, GNMT, KDM3A | FDPS 342/4885MAOB 3790/4885TTR 4808/4885 |
| US-11533912-B2 | Use of cinnamate compounds in the control of fungal diseases of crops | CROCC, GNMT, KDM3A | FDPS 342/4885MAOB 3790/4885TTR 4808/4885 |
| US-20100048893-A1 | Substituted arylalkanoic acid derivatives and use thereof | CYSLTR1, CYSLTR2, LTB4R2 | FDPS 701/4885MAOB 886/4885TTR 3315/4885 |
| US-20040044258-A1 | Substituted phenylalkanoic acid derivatives and use thereof | PTGER1, CYSLTR1, PTGS1 | FDPS 1295/4885MAOB 4115/4885TTR 3222/4885 |
| US-20070213333-A1 | Substituted arylalkanoic acid derivatives and use thereof | CYSLTR1, CYSLTR2, LTB4R2 | FDPS 701/4885MAOB 886/4885TTR 3315/4885 |
| US-20090062530-A1 | Substituted arylalkanoic acid derivatives and use thereof | CYSLTR1, CYSLTR2, LTB4R2 | FDPS 701/4885MAOB 886/4885TTR 3315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.